Previous Close | 2.4000 |
Open | 2.2300 |
Bid | 2.2420 x 0 |
Ask | 2.3720 x 0 |
Day's Range | 2.2300 - 2.2360 |
52 Week Range | 1.7140 - 4.9740 |
Volume | |
Avg. Volume | 78 |
Market Cap | 117.774M |
Beta (5Y Monthly) | 1.26 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.3800 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and year-end report for January to March 2024.
Hansa Biopharma AB (STO: HNSA) expects to report revenue of approximately SEK 54m for Q1 ending March 31, 2024 (preliminary and unaudited), consisting of SEK 48m in product sales and SEK 6m in revenue recognition primarily related to its agreement with Sarepta Therapeutics, Inc. Revenue growth during the first quarter 2024 was driven by product sales in the Company's largest markets including France, UK, and Germany, as well as initial sales in Belgium.
Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced the publication of its 2023 Annual and Sustainability Reports. In 2023, the company made solid progress in both Commercial and R&D priorities and continued its journey to become a default sustainable organization.